Navigation Links
Mycoplasma Pneumoniae (IgM)(Crown Titer Substrate)

ProductsMycoplasma Pneumoniae (IgM)(Crown Titer Substrate)
Company Inverness Medical Innovations
Item Mycoplasma Pneumoniae (IgM)(Crown Titer Substrate)
Features Inquire
Description Inverness Medical Professional Diagnostics is a leading provider of immunofluorescence assays, with an extensive IFA and DFA test menu that includes kits for autoimmune diseases, infectious diseases and STDs as well as miscellaneous conjugates and components. Our Impact IFA Test Systems give you a wide assortment of substrates and kit sizes to choose from. Kit components include substrate slides, controls, conjugate, mounting medium, phosphate-buffered saline (PBS) and ZORBA-NS serum diluents to reduce the nonspecific fluorescence associated with some serum specimens.
Info Inverness Medical Innovations
Customer Service: 800-257-9525
Web site: http://www.invernessmedical.com/

Related medicine products :

1. ImmunoWELL Mycoplasma pneumoniae Antibody (IgG) Test
2. ImmunoWELL Mycoplasma pneumoniae Antibody (IgM) Test
3. MGB Alert Mycoplasma pneumoniae ASR*
4. Mycoplasma pneumoniae IgG II
5. Mycoplasma pneumoniae IgM II
6. Mycoplasma Pneumoniae (IgG)
7. Mycoplasma Pneumoniae (IgG) (Crown Titer Substrate)
8. Mycoplasma Pneumoniae (IgM)
9. Culture, Mycoplasma hominis and Ureaplasma urealyticum
10. Culture, Mycoplasma pneumoniae
11. Genital Mycoplasma Culture
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 1The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 3Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 1Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 234 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 134 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 234 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 334 Outstanding Teachers and Schools Receive 2410 000 Amgen Award for Science Teaching Excellence 49248 4